Canad+-pgb-lip

Canad+-pgb-lip has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Oct 23, 2026: “Particle-based drug eased inflammation, spared defenses in mice”.

Intervention

1 paper studies it3 findingsUpdated Oct 23, 2026

1 new paper in 30 daysSee all 1

None of its findings points the other way.

1 lab in 1 country

Animals1

What did studies of Canad+-pgb-lip find?

Studies of Canad+-pgb-lip measured 3 outcomes; the most studied are inflammation (1 study), vascular and epithelial injury (1) and survival (1).

Inflammation

downin mice1

1 study

Canad+-pgb-lip decreases inflammation in mice.
“curtailed hyperinflammation and effector overactivation across GVHD target organs.”
Animalsallogeneic hematopoietic stem cell transplantation-associated graft-versus-host diseaseGVHD target organs
Particle-based drug eased inflammation, spared defenses in mice
Science advancesOct 23, 2026

Latest

1 paper in 12 months

Science AdvancesOct 23

Particle-based drug eased inflammation, spared defenses in mice

In experiments in mice with immune attacks after stem cell transplants, a particle-based drug improved survival and maintained control of viral or bacterial infections.In experiments in mice with immune attacks after stem cell transplants, a particle-based drug improved survival and maintained control of viral or bacterial infections.

Mouse studyInterventions

Paper

Canad+-pgb-lip

What did studies of Canad+-pgb-lip find?

Latest

Particle-based drug eased inflammation, spared defenses in mice

Related